Cargando…

Early Effects of Nivolumab and Ipilimumab Combined Immunotherapy in the Treatment of Metastatic Melanoma in Poland: A Multicenter Experience

Nivolumab and ipilimumab combination became the first-line standard in advanced melanoma. We assessed its efficacy in a real-life study in Poland. In a one-year follow-up, we evaluated the medical records of 50 melanoma patients treated with that modality in five oncology centers. We recorded therap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pacholczak-Madej, Renata, Grela-Wojewoda, Aleksandra, Puskulluoglu, Mirosława, Lompart, Joanna, Las-Jankowska, Manuela, Krawczak, Katarzyna, Wrona, Ewa, Zaręba, Lech, Żubrowska, Justyna, Walocha, Jerzy, Bazan-Socha, Stanisława, Ziobro, Marek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598919/ https://www.ncbi.nlm.nih.gov/pubmed/36289790 http://dx.doi.org/10.3390/biomedicines10102528

Ejemplares similares

Immune Checkpoint Inhibitor Related Rheumatological Complications: Cooperation between Rheumatologists and Oncologists
por: Pacholczak-Madej, Renata, et al.
Publicado: (2023)

Biomarkers of Trastuzumab-Induced Cardiac Toxicity in HER2- Positive Breast Cancer Patient Population
por: Grela-Wojewoda, Aleksandra, et al.
Publicado: (2022)

Cardiotoxicity Induced by Protein Kinase Inhibitors in Patients with Cancer
por: Grela-Wojewoda, Aleksandra, et al.
Publicado: (2022)

Effects of Transcutaneous Electrical Nerve Stimulation on Pain and Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Systematic Review
por: Püsküllüoğlu, Mirosława, et al.
Publicado: (2022)

Endothelial dysfunction in patients with granulomatosis with polyangiitis: a case–control study
por: Pacholczak, Renata, et al.
Publicado: (2018)

Endothelial dysfunction in patients with systemic sclerosis
por: Pacholczak-Madej, Renata, et al.
Publicado: (2020)

Shifting Treatment Paradigms: Improvements in HR-Positive, HER-2- Negative Breast Cancer Care in Poland from a Clinical Perspective
por: Ziobro, Marek, et al.
Publicado: (2023)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

High prevalence of thrombophilic risk factors in patients with central retinal artery occlusion
por: Dziedzic, Radosław, et al.
Publicado: (2023)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
por: Potluri, Ravi, et al.
Publicado: (2019)

Central Retinal Artery Occlusion Is Related to Vascular Endothelial Injury and Left Ventricular Diastolic Dysfunction
por: Dropiński, Jerzy, et al.
Publicado: (2022)

Citrullinated histone H3, a marker of extracellular trap formation, is increased in blood of stable asthma patients
por: Kuczia, Pawel, et al.
Publicado: (2020)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
por: Nishimura, Yoshito, et al.
Publicado: (2018)

Ipilimumab/nivolumab: Diffuse pneumonitis: case report
Publicado: (2020)

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
por: Towner, Mary, et al.
Publicado: (2022)

Impaired fibrinolysis and lower levels of plasma α(2)-macroglobulin are associated with an increased risk of severe asthma exacerbations
por: Bazan-Socha, Stanislawa, et al.
Publicado: (2017)

Prothrombotic State in Asthma Is Related to Increased Levels of Inflammatory Cytokines, IL-6 and TNFα, in Peripheral Blood
por: Bazan-Socha, Stanislawa, et al.
Publicado: (2017)

Low frequency of HPV positivity in breast tumors among patients from south-central Poland
por: Biesaga, Beata, et al.
Publicado: (2021)

Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
por: Marchetti, Paolo, et al.
Publicado: (2020)

Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
por: Brastianos, Priscilla K., et al.
Publicado: (2021)

Adverse events induced by nivolumab and ipilimumab combination regimens
por: Somekawa, Kohei, et al.
Publicado: (2022)

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
por: Shitara, Kohei, et al.
Publicado: (2022)

Ipilimumab/nivolumab/tozinameran: Various toxicities: case report
Publicado: (2022)

Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients
por: Reichert, Constance, et al.
Publicado: (2023)

Cellular immune response to SARS-CoV-2 in patients with primary antibody deficiencies
por: Mizera, Dorota, et al.
Publicado: (2023)

Editorial to the Special Issue “Pathogenesis and Novel Therapeutics in Asthma”
por: Bazan-Socha, Stanisława, et al.
Publicado: (2023)

Interactions Via α(2)β(1) Cell Integrin May Protect against the Progression of Airway Structural Changes in Asthma
por: Bazan-Socha, Stanislawa, et al.
Publicado: (2021)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
por: Gupta, Mehul, et al.
Publicado: (2023)

Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
por: Suozzi, Kathleen C., et al.
Publicado: (2016)

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
por: Tan, Irena, et al.
Publicado: (2018)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
por: Asher, Nethanel, et al.
Publicado: (2020)

Ipilimumab/nivolumab: Immune-related pneumonitis: 2 case reports
Publicado: (2020)

Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies
por: Zhang, Jason, et al.
Publicado: (2019)

Ipilimumab/nivolumab/tozinameran: Severe necrotizing myopathy: case report
Publicado: (2022)

Cabozantinib/ipilimumab/nivolumab interaction: Haemophagocytic lymphohistiocytosis: case report
Publicado: (2021)

Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms
por: Al-Toubah, T., et al.
Publicado: (2021)

Ipilimumab/nivolumab/tozinameran: Acute myocarditis: 3 case reports
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jmjsja27va45ld7cov3p2s43s1